← All trials

NCT04760314

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Mar 10, 2021
Primary completion
Jul 31, 2022
Completion date
Jan 28, 2023
First posted
Feb 18, 2021
Last posted
Sep 5, 2021
Enrollment
280
Arms / groups
3 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.